• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

粪便微生物移植后早期使用抗生素会增加治疗失败的风险。

Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure.

机构信息

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.

Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

Clin Infect Dis. 2018 Jan 6;66(1):134-135. doi: 10.1093/cid/cix684.

DOI:10.1093/cid/cix684
PMID:29020157
Abstract

Antibiotic use within the first 8 weeks after fecal microbiota transplantation (FMT) may disrupt microbial engraftment and limit FMT effectiveness. We aimed to assess the burden of antibiotic use within 8 weeks of FMT and its impact on FMT efficacy.

摘要

在粪菌移植（FMT）后 8 周内使用抗生素可能会破坏微生物定植并限制 FMT 的效果。我们旨在评估 FMT 后 8 周内抗生素使用的负担及其对 FMT 疗效的影响。

相似文献

1
Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure.粪便微生物移植后早期使用抗生素会增加治疗失败的风险。
Clin Infect Dis. 2018 Jan 6;66(1):134-135. doi: 10.1093/cid/cix684.
2
Predictors of fecal transplant failure.粪便移植失败的预测因素。
Eur J Gastroenterol Hepatol. 2016 Jul;28(7):826-30. doi: 10.1097/MEG.0000000000000614.
3
Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients.采用粪菌移植抢救危重症患者抗生素相关性腹泻。
Crit Care. 2019 Oct 21;23(1):324. doi: 10.1186/s13054-019-2604-5.
4
Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.用于复发性艰难梭菌感染的口服、冷冻粪便微生物群移植（FMT）胶囊。
BMC Med. 2016 Sep 9;14(1):134. doi: 10.1186/s12916-016-0680-9.
5
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.造血干细胞移植受者复发性艰难梭菌感染的粪便微生物群移植
Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5.
6
Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection.万古霉素逐渐减量与复发性艰难梭菌感染患者粪菌移植失败的风险。
Clin Infect Dis. 2017 Oct 1;65(7):1214-1217. doi: 10.1093/cid/cix511.
7
Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.粪便微生物群移植治疗严重和/或复杂性艰难梭菌感染的长期随访研究：一项多中心经验
J Clin Gastroenterol. 2016 May-Jun;50(5):398-402. doi: 10.1097/MCG.0000000000000374.
8
Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.澳大利亚粪便微生物群移植治疗复发性艰难梭菌感染的经济学评估
J Gastroenterol Hepatol. 2016 Dec;31(12):1927-1932. doi: 10.1111/jgh.13402.
9
Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study.粪便微生物群移植治疗艰难梭菌感染后早期失败的预测因素：一项多中心研究
Am J Gastroenterol. 2016 Jul;111(7):1024-31. doi: 10.1038/ajg.2016.180. Epub 2016 May 17.
10
Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience.粪便微生物移植治疗复发性艰难梭菌感染：亚利桑那州梅奥诊所的经验。
Mayo Clin Proc. 2013 Aug;88(8):799-805. doi: 10.1016/j.mayocp.2013.04.022.

引用本文的文献

1
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.粪便微生物群移植：应用场景、疗效预测及影响供体-受体相互作用的因素
Front Microbiol. 2025 Mar 25;16:1556827. doi: 10.3389/fmicb.2025.1556827. eCollection 2025.
2
Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent Infection: A Prospective Multicenter Observational Study.复发性感染患者粪便微生物群移植后抗生素暴露的危险因素：一项前瞻性多中心观察性研究
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf130. doi: 10.1093/ofid/ofaf130. eCollection 2025 Mar.
3
The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection.
用于治疗艰难梭菌感染的活体生物治疗药物的不断演变格局。
Indian J Gastroenterol. 2025 Apr;44(2):129-141. doi: 10.1007/s12664-024-01717-9. Epub 2025 Jan 16.
4
Factors for Treatment Failure After Fecal Microbiota Transplantation in Infection.粪便微生物群移植治疗感染后治疗失败的因素
Microorganisms. 2024 Dec 9;12(12):2539. doi: 10.3390/microorganisms12122539.
5
Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions.通过靶向异基因造血干细胞移植中的肠道微生物群动态来推进移植物抗宿主病的治疗策略：当前证据和未来方向
Mol Med. 2025 Jan 3;31(1):2. doi: 10.1186/s10020-024-01060-x.
6
Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non- Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study.粪便微生物群制剂Live-jslm（REBYOTA®）在接受非感染性抗生素治疗患者中的疗效：一项2期开放标签研究的事后亚组分析
Open Forum Infect Dis. 2024 Jun 17;11(7):ofae341. doi: 10.1093/ofid/ofae341. eCollection 2024 Jul.
7
Identification of donor Bacteroides vulgatus genes encoding proteins that correlate with early colonization following fecal transplant of patients with recurrent Clostridium difficile.鉴定与粪菌移植治疗复发性艰难梭菌患者早期定植相关的供体脆弱拟杆菌编码蛋白的基因。
Sci Rep. 2023 Aug 29;13(1):14112. doi: 10.1038/s41598-023-41128-y.
8
The Evolving Landscape of Fecal Microbial Transplantation.粪便微生物移植的演变格局。
Clin Rev Allergy Immunol. 2023 Oct;65(2):101-120. doi: 10.1007/s12016-023-08958-0. Epub 2023 Feb 9.
9
Effects of a farm-specific fecal microbial transplant (FMT) product on clinical outcomes and fecal microbiome composition in preweaned dairy calves.一种特定于农场的粪便微生物移植（FMT）产品对未断奶奶牛犊牛临床结局和粪便微生物组组成的影响。
PLoS One. 2022 Oct 21;17(10):e0276638. doi: 10.1371/journal.pone.0276638. eCollection 2022.
10
Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for C. difficile Infections Across Academic and Private Clinical Settings.粪菌移植治疗艰难梭菌感染在学术和私立临床机构中的长期疗效及安全性
J Clin Gastroenterol. 2023;57(10):1024-1030. doi: 10.1097/MCG.0000000000001778. Epub 2022 Oct 14.